Phase II Clinical Trial Enrollment Complete – Evaluating rhPDGF-BB in the Reconstruction of Full-Thickness Head or Neck Defects following Skin Cancer Excision
Published on August 19, 2026
Lynch Regenerative Medicine Announces Completion of Enrollment in a Phase II Clinical Trial Evaluating rhPDGF-BB in the Reconstruction of Full-Thickness Head or Neck Defects Following Skin Cancer Excision.
The study reflects LRM’s commitment to supporting rigorous clinical research evaluating rhPDGF-BB in potential applications beyond its currently approved uses.
The use of rhPDGF-BB being evaluated in this study is investigational and has not been approved by the U.S. Food and Drug Administration for this indication. The study remains ongoing, and no conclusions regarding safety or effectiveness can be drawn until the study is completed, and the data are analyzed. The study protocol, informed consent, and other study documents were reviewed and approved by the applicable institutional review board.
